- Home
- CHI vs IMNM Comparison
CHI vs IMNM Comparison
Compare CHI & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- IMNM
- Stock Information
- Founded
- CHI 2002
- IMNM 2006
- Country
- CHI United States
- IMNM United States
- Employees
- CHI N/A
- IMNM N/A
- Industry
- CHI Investment Managers
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- CHI Finance
- IMNM Health Care
- Exchange
- CHI Nasdaq
- IMNM Nasdaq
- Market Cap
- CHI 840.2M
- IMNM 987.1M
- IPO Year
- CHI N/A
- IMNM 2020
- Fundamental
- Price
- CHI $11.16
- IMNM $14.23
- Analyst Decision
- CHI
- IMNM Strong Buy
- Analyst Count
- CHI 0
- IMNM 9
- Target Price
- CHI N/A
- IMNM $24.89
- AVG Volume (30 Days)
- CHI 186.2K
- IMNM 2.0M
- Earning Date
- CHI 01-01-0001
- IMNM 11-12-2025
- Dividend Yield
- CHI 9.90%
- IMNM N/A
- EPS Growth
- CHI N/A
- IMNM N/A
- EPS
- CHI N/A
- IMNM N/A
- Revenue
- CHI N/A
- IMNM $12,589,000.00
- Revenue This Year
- CHI N/A
- IMNM N/A
- Revenue Next Year
- CHI N/A
- IMNM $140.06
- P/E Ratio
- CHI N/A
- IMNM N/A
- Revenue Growth
- CHI N/A
- IMNM 16.74
- 52 Week Low
- CHI $9.70
- IMNM $5.15
- 52 Week High
- CHI $11.61
- IMNM $15.13
- Technical
- Relative Strength Index (RSI)
- CHI 73.43
- IMNM 68.65
- Support Level
- CHI $10.58
- IMNM $11.25
- Resistance Level
- CHI $11.00
- IMNM $14.78
- Average True Range (ATR)
- CHI 0.15
- IMNM 1.02
- MACD
- CHI 0.03
- IMNM 0.38
- Stochastic Oscillator
- CHI 86.36
- IMNM 88.19
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.